Showing results (1-10 of 209) with videos related to
Sort By:
Pageof 21
Cancer Research and Treatment|November 18, 2022
Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation SequencingBeung-Chul Ahn, Ye-Jeong Han, Hye Ryun Kim, et al.Cancer Immunology, Immunotherapy : CII|September 27, 2021
Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceSeoyoung Lee, Hyo Sup Shim, Beung-Chul Ahn, et al.Cancer Medicine|September 16, 2021
A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinomaJi Hyun Lee, Seong Gu Heo, Beung-Chul Ahn, et al.Cancers|August 7, 2021
Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World StudyBeung-Chul Ahn, Jee Hung Kim, Kyoung-Ho Pyo, et al.Lung Cancer (Amsterdam, Netherlands)|April 27, 2023
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyHyunwook Kim, Beung-Chul Ahn, Jiyun Lee, et al.Cancer Treatment and Research Communications|June 12, 2023
Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in KoreaBeung-Chul Ahn, Seoyoung Lee, Jiyun Lee, et al.Brain Tumor Research and Treatment|November 14, 2024
Complete Remission of Dural-Based Leptomeningeal Metastasis in Patient With Non-Small Cell Lung Cancer by OsimertinibJemin Hwang, Beung Chul Ahn, So Hyeon Ji, et al.Cancers|July 2, 2021
Distinct Characteristics and Clinical Outcomes to Predict the Emergence of <i>MET</i> Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsBeung-Chul Ahn, Ji Hyun Lee, Min Hwan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLCMisako Nagasaka, Viola W Zhu, Sun Min Lim, et al.Oncoimmunology|June 26, 2024
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, et al.Pageof 21